Bo Zhang1, Kai Liu2, Jian Zhang3, Liwei Dong3, Zhichao Jin4, Xinji Zhang4, Feng Xue2, Jia He5. 1. Department of Health Statistics, The Second Military Medical UniversityShanghai 200433, China; Center for Disease Control and Prevention, Jinan Military Area CommandJinan 250014, China. 2. Department of Surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University Shanghai 200438, China. 3. National Center for Liver Cancer, Eastern Hepatobiliary Surgery Institute, The Second Military Medical University Shanghai 200438, China. 4. Department of Health Statistics, The Second Military Medical University Shanghai 200433, China. 5. Department of Health Statistics, The Second Military Medical UniversityShanghai 200433, China; Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS)Shanghai 200031, China.
Abstract
BACKGROUND: Adjuvant transcatheter arterial chemoembolization (TACE) is associated with better outcome and reduced tumor recurrence in hepatocellular carcinoma (HCC) patients. This study aimed to investigate the relationship between glutamine synthetase (GS) expression and survival of HCC patients after postoperative adjuvant TACE. METHODS: We retrospectively analyzed 554 HCC patients in two independent cohorts who underwent curative resection. Immunohistochemistry assay was used to investigate the expression of GS protein and evaluate the association with survival and the response to adjuvant TACE. RESULTS: In training cohort, patients with low GS expression who received postoperative adjuvant TACE showed a better overall survival (OS) (P<0.001) and less early phase recurrence (P=0.016). Adjuvant TACE was an independent prognostic factor for 5-year OS (HR=0.408, 95% CI 0.261-0.639, P<0.001) and early phase recurrence (HR=0.592, 95% CI 0.376-0.931, P=0.023). The same result was confirmed in validation cohort. Patients with high GS expression in both cohorts did not have a significant response to adjuvant TACE in OS and early phase recurrence. CONCLUSIONS: GS status in tumor might be a useful tool in the selection of HCC patients who would be likely to benefit from postoperative adjuvant TACE.
BACKGROUND: Adjuvant transcatheter arterial chemoembolization (TACE) is associated with better outcome and reduced tumor recurrence in hepatocellular carcinoma (HCC) patients. This study aimed to investigate the relationship between glutamine synthetase (GS) expression and survival of HCCpatients after postoperative adjuvant TACE. METHODS: We retrospectively analyzed 554 HCCpatients in two independent cohorts who underwent curative resection. Immunohistochemistry assay was used to investigate the expression of GS protein and evaluate the association with survival and the response to adjuvant TACE. RESULTS: In training cohort, patients with low GS expression who received postoperative adjuvant TACE showed a better overall survival (OS) (P<0.001) and less early phase recurrence (P=0.016). Adjuvant TACE was an independent prognostic factor for 5-year OS (HR=0.408, 95% CI 0.261-0.639, P<0.001) and early phase recurrence (HR=0.592, 95% CI 0.376-0.931, P=0.023). The same result was confirmed in validation cohort. Patients with high GS expression in both cohorts did not have a significant response to adjuvant TACE in OS and early phase recurrence. CONCLUSIONS:GS status in tumor might be a useful tool in the selection of HCCpatients who would be likely to benefit from postoperative adjuvant TACE.
Authors: Silvia Tremosini; Alejandro Forner; Loreto Boix; Ramon Vilana; Luis Bianchi; Maria Reig; Jordi Rimola; Carlos Rodríguez-Lope; Carmen Ayuso; Manel Solé; Jordi Bruix Journal: Gut Date: 2012-01-27 Impact factor: 23.059
Authors: W S van der Hel; R G E Notenboom; I W M Bos; P C van Rijen; C W M van Veelen; P N E de Graan Journal: Neurology Date: 2005-01-25 Impact factor: 9.910
Authors: Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544